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Preclinical Studies of a Specific PPARc Modulator in
the Control of Skin Inflammation
Arianna Mastrofrancesco1, Daniela Kovacs1, Massimiliano Sarra2, Emanuela Bastonini1, Giorgia Cardinali1,
Nicaela Aspite1, Emanuela Camera1, Philippe Chavatte3, Pierre Desreumaux4, Giovanni Monteleone2 and
Mauro Picardo1
Peroxisome proliferator–activated receptor g (PPARg) antagonizes inflammatory signals by interfering with NF-kB
nuclear translocation. Consistently, PPARg agonists have been proposed in various inflammatory skin disorders,
but their wide use has been limited by severe side effects. Classes of compounds with specific PPARg agonism
have been designed to selectively target inflammatory pathways. Among these compounds, GED-0507-34L has
been developed and recently used in phase II clinical trials for inflammatory bowel diseases. This study was
aimed at assessing the role of GED-0507-34L in preclinical models of inflammatory skin diseases. The compound
modulated PPARg function and suppressed the inflammatory process inhibiting NF-kB nuclear translocation with
the consequent reduction of inflammatory cytokines expression, such as IL-6, IL-8, IL-12, IL-21, IL-23, tumor
necrosis factor-a (TNF-a), and cyclooxygenase-2 (COX-2) in normal human keratinocytes and lymphocytes treated
with lipopolysaccharide (LPS) or TNF-a. Moreover, an altered proliferation and expression of differentiation
markers induced by TNF-a were also counteracted. In psoriasis-like skin lesions elicited in mice by IL-21, topical
application of GED-0507-34L reduced cellular infiltrate and epidermal hyperplasia, normalizing the differentiation
process. The results indicate that GED-0507-34L possesses anti-inflammatory properties useful for the manage-
ment of patients with inflammatory skin diseases including psoriasis. Phase I trial on patients is ongoing.
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INTRODUCTION
Peroxisome proliferator–activated receptors (PPARs) are
ligand-activated transcription factors and members of the
nuclear hormone receptor superfamily. Three PPAR isotypes,
a, b/d, and g, have been identified with different tissue
distribution and responsiveness to ligands (Michalik and
Wahli, 2007; Cariou et al., 2012). PPAR activation regulates
glucose and lipid metabolism, cell differentiation, and several
activities of many nonimmune and immune cells (Sertznig
et al., 2008; Sertzing and Reichrath, 2011). In particular,
PPARg activation downmodulates the synthesis of
inflammatory cytokines in T cells, monocytes, macrophages,
and mast cells (Sugiyama et al., 2000; Marx et al., 2002;
Henson, 2003), regulates keratinocyte proliferation and
differentiation (Mao-Qiang et al., 2004; Demerjian et al.,
2006), and improves permeability barrier homeostasis (Man
et al., 2006). Therefore, PPARg has become an attractive target
for therapeutic interventions in inflammatory skin diseases
associated with aberrant differentiation and proliferation of
keratinocytes (Pasparakis, 2009; Nestle et al., 2009a). PPARg
agonists exert an anti-inflammatory effect partly dependent on
the ability to antagonize other transcription factors, such as
members of the NF-kB and activator protein-1 families, having
a key role in inflammatory processes (Delerive et al., 2000,
2001; Pascual and Glass, 2006). PPARg agonists belonging to
the thiazolidine-2,4-diones class are currently used in the
treatment of type 2 diabetes for their ability to induce insulin
sensitization and improve glycemic control (Semple et al.,
2006). The systemic administration of troglitazone (Tg) and
pioglitazone improved skin lesions in psoriatic patients,
whereas rosiglitazone was ineffective either systemically or
topically. The wide use of thiazolidine-2,4-diones in psoriasis,
however, has been limited because of possible adverse effects
(Kuenzli and Saurat, 2003; Nesto et al., 2003; Bongartz et al.,
2005; Shafiq et al., 2005; Ellis et al., 2007; Yang and
Soodvilai, 2008; Malhotra et al., 2012). Based on their
chemical structure, agonists of PPARg determine several
conformational changes of the receptor with a consequent
regulation of different patterns of genes. Therefore, specific
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PPARg modulators have been developed to selectively regulate
the anti-inflammatory process reducing the interference with
lipid metabolism (Sears et al., 2007; Bhalla et al., 2011;
Liberato et al., 2012). In this view, we studied the chemical
entity (R)-(3)-(4-Aminophenyl)-2-methoxypropionic acid (GED-
0507-34L; Supplementary Figure S1 online) (Rousseaux et al.,
2005; Pirat et al., 2012; Wahli and Michalik, 2012) as docking
simulation predicted the binding into the active site of PPARg
(Supplementary Figure S1 online). In order to better character-
ize the role of PPARg in controlling skin homeostasis, we
assessed the regulatory effect of GED-0507-34L in cultures of
normal human keratinocytes (NHKs) and peripheral blood
mononuclear cells (PBMCs) exposed to multiple inflammatory
stimuli as well as the ability of the compound to interfere with
the NHK proliferation and differentiation processes. In a
further set of experiments we evaluated the same effects
in vivo using a murine model of psoriasis-like epidermal
hyperplasia induced by IL-21 (Caruso et al., 2009).
GED-0507-34L did not display any side effects even at very
high concentrations (2,000 mg kg 1) in toxicological studies
performed in rats, dogs, and rabbits (unpublished observa-
tions). A phase II clinical trial for the treatment of Crohn’s
disease is ongoing (EUDRACT NUMBER 2012-001662-15)
and no relevant side effects particularly on lipid metabolism
have been reported up to now.
RESULTS
PPARc: binding and specific activation in NHKs
The binding of GED-0507-34L to PPARg was assessed by
molecular modeling studies. GED-0507-34L fitted with the
PPARg ligand binding domain, interacting through hydrogen
bound (SER289, Tyr473, HIS449, and His323) considered as
the key molecular determinants required for ligand recogni-
tion and PPARg activation (Supplementary Figure S1 online).
Increasing doses of GED-0507-34L (0.01–4 mM) showed no
significant changes in terms of metabolic activity and viability
in NHKs at different times (24–48 hours; data not shown).
Concentrations between 0.01 and 1 mM were chosen to
analyze mRNA expression and transcriptional activity of
PPARg using Tg as positive control (Qiang et al., 2004;
Mastrofrancesco et al., 2010). Increased PPARg transcript at
6 hours and enhanced luciferase expression at 24 hours were
evident in treated cells in a dose-dependent manner (Figure 1a
and b), whereas PPARa and b/d mRNA expression were not
affected (Figure 1c). Moreover, PPARg mRNA level in
response to GED-0507-34L was also induced after silencing
of PPARa and PPARb/d (Figure 1d and e). All these data
indicate the specific activity of the molecule on the PPARg
isoform. In order to define the gene pattern activated by GED-
0507-34L, 91 PPARg target genes, which were selected
because they all reported to be significantly modified by Tg,
pioglitazone, and rosiglitazone (Sears et al., 2007), were
analyzed. GED-0507-34L was tested at 1 mM, i.e., the
highest concentration used to investigate the effect on cell
proliferation and differentiation. Among those evaluated, only
10 genes were significantly upmodulated, 4 correlating with
lipid metabolism, 2 regulating the activity of the cytochrome
P450, and 4 controlling the transactivation of other genes or
growth factors (RAS and HIF1A), whereas 1, which regulates
cell adhesion, was downmodulated (Supplementary Table S1
online).
Inhibition of inflammatory response in NHKs
The effect of GED-0507-34L on the expression of several
inflammatory molecules was investigated in NHKs stimulated
with tumor necrosis factor-a (TNF-a; 10 ng ml1) or lipopoly-
saccharide (LPS; 10mg ml1) that, binding different membrane
receptors, converge into the NF-kB, a target of PPARg
activation (Delerive et al., 2001). GED-0507-34L
significantly reduced TNF-a and LPS-induced expression of
IL-6, IL-8, and TNF-a mRNA (6 hours; Figure 2a and b) and
protein levels (24 hours) in a dose-dependent manner
(Figure 3a and b). In the same experiment, Tg treatment
reduced cytokine mRNA expression at 6 hours and the protein
levels at 24 hours (Supplementary Table S3 online).
The effect of GED-0507-34L was also evaluated on cycloox-
ygenase-2 (COX-2) expression, a proinflammatory enzyme
that represents a chief target for the treatment of inflammatory
diseases. Treatment of NHKs with LPS significantly increased
COX-2 mRNA, and this induction was inhibited by GED-
0507-34L. Similar inhibitory effect of GED-0507-34L was seen
in NHKs stimulated with TNF-a (data not shown). No change
in COX-2 mRNA was observed in cells treated with GED-
0507-34L alone (0.5 mM for 3 hours; Figure 2c).
The effect of GED-0507-34L on cytokine secretion was
counteracted by the PPARg inhibitor GW9662, supporting the
PPARg-dependent mechanism (Figure 2d and e). By using
same concentrations, GED-0507-34L significantly reduced
LPS-stimulated TNF-a, IL-12, IL-21, and IL-23 production even
in PBMCs (Figure 3c–f), confirming its anti-inflammatory
properties.
PPARg activation controls the expression of inflammatory
mediators by interfering with NF-kB through a transrepression
mechanism (Li and Engelhardt, 2005), and therefore we
evaluated the capability of GED-0507-34L to activate this
pathway. The compound upregulated IkBa protein expression
at 30 minutes, maintained until 2 hours, and significantly
reduced the IkBa protein degradation induced by TNF-a
(Figure 4a and b). The reduction of NF-kB p65 nuclear
translocation was confirmed by immunofluorescence analyses
(Figure 4c). In PPARg-silenced cells (Figure 4d) GED-0507-34L
did not inhibit IkBa degradation either after LPS or TNF-a
treatment (Figure 4e and f) and consequently the expression of
TNF-a, IL-8, and K6 were not modified (Figure 4g and h). On
the contrary, in PPARa/PPARb/d-silenced NHKs, GED-0507-
34L was able to significantly reduce LPS-induced TNF-a and
IL-8 mRNA expression (Figure 4i).
All these data indicate that GED-0507-34L interferes with
the activation of NF-kB pathway and the generation of
proinflammatory molecules by PPARg-mediated mechanism.
GED-0507-34L normalized TNF-a-induced proliferation and
altered differentiation in NHKs
GED-0507-34L (0.5 and 1 mM) significantly counteracted the
TNF-a-induced altered keratinocytes proliferation as demon-
strated by the reduction of Ki67 and the increase of p21
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expression (Figure 5a–c) as well as the abnormal keratinocytes
differentiation, as detected by reduced expression of filaggrin
(FLG) and loricrin (LOR) in high calcium condition (Kim et al.,
2011; Ishitsuka et al., 2013) (Figure 5e and Supplementary
Figure S2 online). Moreover, GED-0507-34L significantly
reduced the expression of K6, an inflammatory- and prolifera-
tion-associated keratin (Weiss et al., 1984; Navarro et al.,
1995; Tomic-Canic et al., 1998) expressed in activated
keratinocytes in response to TNF-a without affecting the
basal mRNA K6 level (Figure 5d). In low calcium medium,
GED-0507-34L promoted cell differentiation (data not shown).
These findings demonstrate the ability of GED-0507-34L
to regulate the altered keratinocyte proliferation and
differentiation.
GED-0507-34L normalized IL-21-induced epithelial hyperplasia,
differentiation, and inflammatory markers in mice
In order to confirm in vivo the properties of GED-0507-34L,
we used a mouse model of psoriasis-like epidermal prolifera-
tion induced by intradermal injection of IL-21, a cytokine
highly expressed in psoriatic plaques with a key role in the
pathogenesis of the disease (Caruso et al., 2009). A psoriasis-
like form of epidermal hyperplasia associated with
hyperkeratosis, parakeratosis, and lymphocytes infiltrate in
the dermis was induced by IL-21 (Figure 6a). PPARg expres-
sion was not modified by the procedure (Figure 6d). Topical
application of 1 mg at 50 mM (1%) GED-0507-34L for 6 days
significantly improved the epidermal hyperplasia, hyperker-
atosis, and parakeratosis (Figure 6b), as well as the edema and
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Figure 1. Expression and activation of peroxisome proliferator–activated receptor c (PPARc) in GED-0507-34L-treated normal human keratinocytes
(NHKs). (a) Real-time PCR analysis of the expression of PPARg in NHKs treated with GED-0507-34L (0.01–1 mM) for 6 hours. Troglitazone (Tg) treatment (5mM) was
used as a positive control. (b) Luciferase activity analysis of cells transfected with pGL3-(Jwt)3TKLuc reporter construct, treated with GED-0507-34L (0.01–1 mM)
and Tg (5mM) for 24 hours. (c) Real-time PCR analysis of the expression of PPARg, PPARa, and PPARb/d in NHKs treated with GED-0507-34L (0.5mM) for
6 hours (n¼ 3; *Po0.05; **Po0.01; ***Po0.001). (d) NHKs were co-transfected with PPARa and PPARb/d small interfering RNAs (siRNAs) or with
nonspecific siRNA (siCtr). PPARa and PPARb/d levels were evaluated by real-time PCR (*Po0.01). (e) Real-time PCR analysis of the expression of PPARg in
PPARa/PPARb/d-deficient cells in response to GED-0507-34L (0.5 mM; ***Po0.001).
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the mononuclear cell infiltrate, as assessed by image analysis
(Figure 6c). The reduction in epidermal cell proliferation
(Figure 6h) was associated with a decrease of K6 and
involucrin and a slight increase of K1 mRNA (Figure 6g–j).
On the contrary, loricrin mRNA expression, not modified by
IL-21, was not affected (Figure 6k). Moreover, the treatment
significantly decreased IL-21 and TNF-a mRNA expression
(Figure 6e and f). Overall, the data indicate the capability of
the molecule to improve both the altered epidermal prolifera-
tion and differentiation and the inflammatory network in this
specific psoriasis-like mouse model.
DISCUSSION
PPARg represents a major research target for the understand-
ing and treatment of different skin diseases, particularly
those related to a chronic inflammatory state (Sertzing and
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Figure 2. Suppression of proinflammatory mediators in response to GED-0507-34L. Real-time PCR analysis of the expression of IL-6, IL-8, and tumor
necrosis factor-a (TNF-a) in normal human keratinocytes (NHKs) stimulated with (a) TNF-a (10 ng ml 1) and (b) lipopolysaccharide (LPS) (10mg ml1) in the
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Reichrath, 2011). Several cytokines are involved in the
pathogenesis of inflammatory skin diseases (Blackwell and
Christman, 1997). Specifically, TNF-a, IL-6, and IL-8 produced
by NHKs, as well as TNF-a, IL-12, IL-21, and IL-23 produced
by PBMCs play a key role in psoriasis (Lowes et al., 2007;
Fridman et al., 2011). The expression of these cytokines in
lesional areas and clinical activity of neutralizing antibodies
has been reported (Gottlieb, 2005). In psoriatic plaques,
PPARg expression is decreased (Hegazy et al., 2012),
suggesting that defective activation of PPARg-driven
intracellular pathways can be involved in psoriatic skin-
damaging inflammatory response (Westergaard et al., 2003).
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Figure 3. Suppression of proinflammatory cytokines in response to GED-0507-34L on normal human keratinocytes (NHKs) and peripheral blood mononuclear
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In mouse models of hyperproliferative and inflammatory skin
diseases, topical application of PPARg ligands reduces
epidermal hyperplasia, normalizes keratinocytes differentia-
tion (Mao-Qiang et al., 2004; Bhagavathula et al., 2005;
Demerjian et al., 2006), and improves permeability barrier
homeostasis without affecting normal skin (Man et al., 2006).
Moreover, the inflammation mediated by T helper type 1 cell
(Th1)–related cytokines is significantly reduced (Hatano et al.,
2010). On the contrary, in mouse models of atopic dermatitis,
PPARg inducers are not able to counteract the Th2-mediated
inflammatory process, such as infiltration of CRTh2-positive
cells and mast cell degranulation (Hatano et al., 2010; Chiba
et al., 2012), whereas PPARa inducers are effective. As PPARg
transcriptional activity depends on specific modification of the
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Figure 5. GED-0507-34L normalizes the altered keratinocyte proliferation/differentiation induced by tumor necrosis factor-a (TNF-a). (a) Immunofluorescence
analysis of Ki67 expression (red) in normal human keratinocytes (NHKs) following TNF-a (10 ng ml1) in the presence or absence of GED-0507-34L (0.5 and
1 mM). Nuclei are counterstained with 4’,6-diamidino-2-phenylindole (DAPI). Bar¼20mm. (b) Percentage of Ki67-positive cells after 72 hours of treatment. (c)
Western blot analysis of p21 expression on NHKs stimulated with TNF-a (10 ng ml1) for 48 hours in the presence or absence of GED-0507-34L (0.5 and 1 mM).
Densitometric scanning of band intensities was used to quantify change of protein expression. A representative blot is shown. (d) Real-time PCR analysis of the
expression of K6 in NHKs stimulated with TNF-a (10 ng ml1) for 6 and 24 hours in the presence or absence of GED-0507-34L (0.5mM) (n¼ 3; 1Po0.01 vs.
untreated control cell; *Po0.05 vs. stimulated cells). (e) mRNA transcript level of filaggrin (FLG) and loricrin (LOR) evaluated by real-time PCR in NHKs stimulated
with TNF-a (20 ng ml1) in high calcium condition for 24 hours in the presence or absence of GED-0507-34L (0.5 and 1 mM) (n¼ 3; *Po0.01 vs. untreated control
cells; 1Po0.05; yPo0.05; *Po0.01 vs. stimulated cells).
Figure 4. Suppression of the inflammatory response through peroxisome proliferator–activated receptor c (PPARc) signaling induced by GED-0507-34L.
(a) Western blotting analysis of IkBa in normal human keratinocytes (NHKs) after treatment with GED-0507-34L (0.5 mM) for 30 minutes until 2 hours. A
representative experiment is shown. (b) Western blotting analysis of IkBa in NHKs after treatment with tumor necrosis factor-a (TNF-a; 10 ng ml1) for 30 minutes
alone or in the presence of GED-0507-34L. A representative experiment is shown. (c) Immunofluorescence analysis of NF-kB p65 (red) in NHKs stimulated with
TNF-a (10 ng ml1) for 30 minutes alone or in the presence of GED-0507-34L. Nuclei are stained with 4’,6-diamidino-2-phenylindole (DAPI). Bar¼ 20mm. (d)
NHKs were transfected with small interfering RNA (siRNA) specific for PPARg (siPPARg) or nonspecific siRNA (siCtr). PPARg level was evaluated by real-time PCR
(*Po0.01). (e, f) Western blotting analysis of IkBa in NHKs transfected with PPARg siRNA or siCtr and stimulated with TNF-a (10ng ml1) and lipopolysaccharide
(LPS; 10mg ml 1) alone or in the presence of GED-0507-34L (0.5mM). (g) Real-time PCR analysis of the expression of TNF-a and IL-8 in NHKs transfected with
PPARg siRNA or siCtr and stimulated with LPS (10mg ml1) for 6 hours in the presence or absence of GED-0507-34L (0.5 mM) (1Po0.01 vs. untreated control cells;
*Po0.05 vs. stimulated cells). (h) Real-time PCR analysis of the expression of K6 in NHKs transfected with PPARg siRNA or siCtr and stimulated with TNF-a
(10 ng ml1) for 6 hours in the presence or absence of GED-0507-34L (0.5 mM) (yPo0.01 vs. untreated control cells; *Po0.05 vs. stimulated cells). (i) Real-time
PCR analysis of the expression of TNF-a and IL-8 in NHKs co-transfected with PPARa and b/d -siRNA or siCtr and stimulated with LPS (10mg ml1) for 6 hours in
the presence or absence of GED-0507-34L (0.5 mM) (n¼3; 1Po0.01 vs. untreated control cells; *Po0.05, **Po0.01 vs. stimulated cells).
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three-dimensional conformation induced by ligands, a number
of selective PPARg modulators driving distinct gene expression
profiles with supposedly reduced side effects are under
investigation (Sears et al., 2007, Higgins and De Paoli,
2010, Pirat et al., 2012). Our data demonstrate that the
chemical entity GED-0507-34L, through the activation of
PPARg, exerts powerful anti-inflammatory activities in vitro
and in vivo with a limited interference with the expression of
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Figure 6. Reduction of IL-21 epithelial hyperplasia, hyperproliferation/differentiation, and inflammatory markers in mice in response to GED-0507-34L. Skin
biopsies were taken from C57BL6 WT mice (n¼9) injected intradermally with 500 ng IL-21 or vehicle, and topically treated with placebo or GED-0507-34L
(50 mM) and killed at day 6. (a) Representative hematoxylin and eosin (H&E)–stained sections. Bar¼20mm. (b) Epidermal thickness measured at day 6 (*Po0.05;
**Po0.01). (c) Inflammatory infiltrate measurement. Real-time PCR analysis of the expression of (d) peroxisome proliferator–activated receptor g (PPARg), (e) IL-21,
(f) tumor necrosis factor-a (TNF-a), and (g) K6. (h) Epidermal proliferation was evaluated by immunohistochemical analysis of proliferating cell nuclear antigen
(PCNA). Real-time PCR analysis of the expression of (i) K1, (j) involucrin, and (k) loricrin. Data are shown as mean value±SE (*Po0.05; **Po0.01).
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genes involved in lipid and glucose metabolism. The ability of
GED-0507-34L to interfere with the inflammatory process has
been demonstrated by significant inhibition, in NHKs and
PBMCs, of proinflammatory cytokine production induced by
TNF-a or LPS that, while interacting with specific membrane
receptors such as TNFR or Toll-like receptor 4 ,leads to NF-kB
translocation through distinct intracellular pathways.
Consistently, GED-0507-34L counteracts the degradation of
IkBa and increases its protein expression, thus preventing the
nuclear translocation of NF-kB. The activation of PPARg is
functionally relevant for the anti-inflammatory properties of
GED-0507-34L, as the molecule fails to prevent IkBa
degradation and cytokine production in PPARg-deficient
cells or in the presence of GW9662 antagonist. The
specificity for PPARg is confirmed by the inhibition of LPS-
induced TNF-a and IL-8 in PPARa/PPARb/d-deficient cells.
GED-0507-34L also interferes with the production of
inflammatory lipid mediators through the downmodulation
of LPS or TNF-a-induced mRNA level of COX-2 that promotes
the synthesis of prostaglandin E2, contributing to amplify the
inflammatory reaction (Shin et al., 2009). Considering the
limited target genes regulated by GED-0507-34L and the early
effect on NF-kB, the activity of the molecule is likely to be
related to a transrepression mechanism that consists of a
PPARg interference with other transcription factors through a
protein–protein interaction (Pascual and Glass, 2006). As
reported for other PPARg modulators (Mao-Qiang et al.,
2004), the molecule induces the expression of differentiation
markers in proliferative keratinocytes and counteracts their
alterations induced by TNF-a (Kim et al., 2011; Ishitsuka et al.,
2013). Again, these effects appear mediated by PPARg, as their
modulation fails in PPARg-silenced keratinocytes. All these
data demonstrate a pleiotropic effect of GED-0507-34L.
The in vitro data have been confirmed in the murine model
of IL-21-induced psoriasis-like epidermal hyperplasia. The
histopathological features induced by intradermal IL-21 injec-
tion included epidermal hyperplasia with aberrant terminal
differentiation and infiltration of mononuclear leukocytes into
the dermis and epidermis (Caruso et al., 2009; Sarra et al.,
2011). Topical application of GED-0507-34L at
concentrations comparable to those effective in vitro
significantly reduces epidermal proliferation and
inflammatory reaction after 1 week of treatment.
In conclusion, our preclinical data indicate that GED-0507-
34L, modulating PPARg activation, can be useful for the
treatment of inflammatory skin diseases associated with
altered keratinocyte differentiation and proliferation, such as
psoriasis. A phase I clinical trial on 16 patients is ongoing
using 1% topical GED-0507-34L.
MATERIALS AND METHODS
Cell culture
Primary cultures of NHKs were isolated and grown as previously
described (Kovacs et al., 2012). All the experiments were performed
at least in duplicate and five different donors were used. PBMCs
from psoriatic patients and healthy controls were isolated by Ficoll-
Hypaque density gradient and maintained in RPMI-1640 (Invitrogen,
Life Sciences, Milan, Italy) supplemented with antibiotics, glutamine,
and fetal bovine serum. For the experiments, PBMCs were stimulated
with LPS (1mg ml 1) in the presence or not with GED-0507-34L
(0.01–0.5 mM) RPMI-1640 without fetal bovine serum to exclude
any interference of the fetal bovine serum with the treatments. The
study was approved by the Medical Ethical Committee of the San
Gallicano Dermatologic Institute and was conducted according to the
Declaration of Helsinki Principles. Participants gave their written
informed consent.
RNA extraction and real-time reverse transcriptase–PCR
Total RNA from NHKs was isolated and processed as previously
described (Flori et al., 2011).
RNA from mice skin was extracted using Trizol reagent according
to the manufacturer’s instructions (Invitrogen). PCR was performed
using a SYBR green–based PCR (Bio-Rad, Milan, Italy). RNA was
reverse transcribed and amplified using the following conditions:
denaturation 1 minute at 95 1C, annealing 30 seconds at 58 1C for all
genes and 60 1C for b-actin, followed by 30 seconds of extension at
72 1C. Sequences of all primers used are indicated in Supplementary
Table S2 online. IL-21 was analyzed using TaqMan based assays
(Applied Biosystems, Darmstadt, Germany) and the iQ Supermix (Bio-
Rad).Gene expression was calculated using the 2DDCT threshold
(CT) algorithm.
Cytokine analysis
IL-6, IL-8, IL-12, IL-21, IL-23, and TNF-a release were measured using
a commercially available ELISA (SearchLight human 4-Plex Array,
Tema Ricerca, Bologna, Italy). Cytokine levels were measured in
duplicate for each condition and expressed as pg per mg protein.
Transient transfection
NHKs (1 106 cells) were transfected with 2.5mg pGL3-(Jwt)3TKLuc
reporter construct (Rocchi et al., 2001) using Amaxa human
keratinocyte Nucleofector kit (Lonza, Basel, Switzerland). A pTK-
Renilla-expressing vector was also transfected as an internal control.
After 24 hours of transfection, cells were exposed to GED-0507-34L
(0.01–1 mM) (provided by Giuliani SpA, Milan, Italy) and Tg (5mM,
Sigma-Aldrich, Milan, Italy). After treatment, cells were harvested in
100ml lysis buffer and 20ml of the extract was assayed for luciferase
activity using Promega’s Dual Luciferase (Promega, Madison, WI)
according to the manufacturer’s protocol. The luciferase activity was
expressed as fold of the activity obtained in cells treated divided by
luciferase activity from nonstimulated cells.
RNA interference experiments
For the RNA interference experiments, NHKs were transfected with
100 pmol small interfering RNA (human) specific for PPARg, PPARa,
and PPARb/d (Santa Cruz Biotechnology, Santa Cruz, CA). An
equivalent amount of nonspecific small interfering RNA was used
as a negative control. Cells were transfected as previously described
(Flori et al., 2011).
Western blotting analysis
The cytoplasmic proteins isolated using a ReadyPrep protein extrac-
tion kit were processed as previously reported (Flori et al., 2011).
Membranes were incubated with anti-IkBa (1:500 dilution, Santa
Cruz Biotechnology), anti-p21 (1:1,000 dilution, Santa Cruz Bio-
technology). Polyclonal antibody b-tubulin (Sigma-Aldrich) was used
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to estimate the protein equal loading. Densitometric analysis was per-
formed using a GS-800 Calibrated Image Densitometer (Bio-Rad).
Animals
C57BL/6 wild-type mice (Harlan, Udine, Italy), 6–8-weeks old, were
used for the in vivo experiments. Mice were maintained in standard
animal cages under specific pathogen-free conditions in the animal
facility at the University Tor Vergata (Rome, Italy). Experiments were
approved by the local ethics committee.
In vivo mouse studies
Mice were intradermally injected with silica microparticles (Kisker-
Biotech, Steinfurt, Germany) coated or not (vehicle) with 500 ng IL-21
(R&D Systems, Minneapolis, MN). Mice, epilated at day  3, were
treated with IL-21-coated or not coated beads at day 0. Mice treated
with IL-21-coated beads were topically treated with a cream contain-
ing GED-0507-34L at 50 mM or placebo from day 1 to day 5. At day
6, mice were killed and skin samples collected for histopathological
and RNA analyses.
Histopathological analysis
Frozen sections were stained with hematoxylin and eosin (Sigma-
Aldrich). Epidermal thickness was assessed as previously described
(Caruso et al., 2009). Inflammatory infiltrate was measured in three
different fields for each sample using the Axiovision 4.7.1 (Zeiss,
Oberkochen, Germany) and values are expressed as fold change
relative to vehicle that was set as 100. Cell proliferation was
determined using PCNA staining kit (Zymed Laboratories, Life
Technologies, Invitrogen, Carlsbad, CA).
Statistical analysis
Statistically significant differences were calculated using Student’s
t-test and Mann–Whitney test. The minimal level of significance
was Po0.05.
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